[go: up one dir, main page]

TNSN97040A1 - Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation. - Google Patents

Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.

Info

Publication number
TNSN97040A1
TNSN97040A1 TNTNSN97040A TNSN97040A TNSN97040A1 TN SN97040 A1 TNSN97040 A1 TN SN97040A1 TN TNSN97040 A TNTNSN97040 A TN TNSN97040A TN SN97040 A TNSN97040 A TN SN97040A TN SN97040 A1 TNSN97040 A1 TN SN97040A1
Authority
TN
Tunisia
Prior art keywords
preparation
treatment
pharmaceutical compositions
osteoporosis
mixed pharmaceutical
Prior art date
Application number
TNTNSN97040A
Other languages
English (en)
Inventor
Zhu Ke Hua
D Thompson David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN97040A1 publication Critical patent/TNSN97040A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT UNE QUANTITE THERAPEUTIQUEMENT EFFICACE D'UN AGONISTE/ANTAGONISTE D'OESTROGENE ET UNE QUANTITE THERAPEUTIQUEMENT EFFICACE D'UNE PROSTAGLANDINE. ELLE CONCERNE EGALEMENT DES PROCEDES POUR LEUR PREPARATION. APPLICATION: UTILISATION DE CES COMPOSITIONS POUR LE TRAITEMENT D'AFFECTIONS DU TISSU OSSEUX, COMPRENANT L'OSTEOPOROSE.
TNTNSN97040A 1996-02-28 1997-02-26 Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation. TNSN97040A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28

Publications (1)

Publication Number Publication Date
TNSN97040A1 true TNSN97040A1 (fr) 2005-03-15

Family

ID=21754846

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97040A TNSN97040A1 (fr) 1996-02-28 1997-02-26 Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.

Country Status (44)

Country Link
US (2) US6323232B1 (fr)
EP (3) EP0883404B1 (fr)
JP (2) JPH11504352A (fr)
KR (1) KR19990087337A (fr)
CN (5) CN1515316A (fr)
AP (3) AP975A (fr)
AR (2) AR005987A1 (fr)
AT (1) ATE405273T1 (fr)
AU (1) AU703285B2 (fr)
BG (1) BG64582B1 (fr)
BR (1) BR9612533A (fr)
CA (1) CA2247420C (fr)
CL (1) CL2004000119A1 (fr)
CO (1) CO4761063A1 (fr)
CZ (1) CZ297452B6 (fr)
DE (1) DE69637651D1 (fr)
DK (1) DK0883404T3 (fr)
DZ (1) DZ2186A1 (fr)
ES (1) ES2312169T3 (fr)
GT (2) GT199700009A (fr)
HN (1) HN1996000101A (fr)
HR (1) HRP970118A2 (fr)
HU (1) HUP9904123A3 (fr)
ID (1) ID19886A (fr)
IL (3) IL154380A0 (fr)
IS (1) IS4812A (fr)
MA (1) MA26420A1 (fr)
NO (2) NO323648B1 (fr)
NZ (1) NZ323456A (fr)
OA (1) OA10837A (fr)
PE (2) PE20011302A1 (fr)
PL (2) PL187219B1 (fr)
PT (1) PT883404E (fr)
RU (1) RU2190395C2 (fr)
SI (1) SI0883404T1 (fr)
SK (1) SK118398A3 (fr)
TN (1) TNSN97040A1 (fr)
TR (1) TR199801679T2 (fr)
TW (1) TW464496B (fr)
UA (1) UA69372C2 (fr)
UY (1) UY24472A1 (fr)
WO (1) WO1997031640A1 (fr)
YU (1) YU7797A (fr)
ZA (1) ZA971719B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6531485B2 (en) 1997-06-23 2003-03-11 Pfizer Inc. Prostaglandin agonists
CA2303799A1 (fr) * 1997-09-09 1999-03-18 Mark Walden Lundy Procede d'augmentation du volume osseux
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (fr) 1998-02-23 2000-02-23 Pfizer Products Inc. Traitement d' anomalies du squelette
NZ508057A (en) * 1998-06-03 2003-07-25 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
PA8475901A1 (es) * 1998-06-16 2000-05-24 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
HRP20000857A2 (en) * 1998-06-16 2001-10-31 Pfizer Prod Inc Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
ES2220005T3 (es) * 1998-06-16 2004-12-01 Pfizer Products Inc. Combinaciones terapeuticas que comprenden un modulador selectivo del receptor de estrogeno y prostaglandina e2.
EP1004306A3 (fr) * 1998-08-06 2000-06-07 Pfizer Products Inc. Agonistes/antagonistes de l'estrogène
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
OA11670A (en) 1998-11-03 2005-01-12 Pfizer Prod Inc Novel macrolide antibiotics.
JP2002538122A (ja) * 1999-03-05 2002-11-12 ザ プロクター アンド ギャンブル カンパニー 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
AU785199B2 (en) * 2000-06-01 2006-11-02 Watson Pharmaceuticals, Inc. Transdermal delivery of lasofoxifene
EP1192945A3 (fr) * 2000-09-21 2004-03-03 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter l'ostéoarthrite
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
ATE288303T1 (de) * 2000-11-30 2005-02-15 Pfizer Prod Inc Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
KR20070087078A (ko) * 2001-07-23 2007-08-27 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하 질환의치료제
CN1599606A (zh) * 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
RU2344819C1 (ru) * 2007-07-16 2009-01-27 Государственное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию" Способ лечения посттравматического нейродистрофического синдрома
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2849910A1 (fr) 2011-09-30 2013-04-04 Perio Sciences, Llc Compositions antioxydantes pour le traitement de l'inflammation ou de dommages oxydatifs
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
PT3525774T (pt) 2016-10-11 2022-03-30 Univ Duke Tratamento de cancro da mama re+ com lasofoxifeno
WO2019199891A1 (fr) 2018-04-10 2019-10-17 Duke University Traitement du cancer du sein avec du lasofoxifène
CN112384634B (zh) * 2018-04-24 2024-04-16 深圳华大生命科学研究院 骨质疏松生物标志物及其用途
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (fr) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
EP0002097B1 (fr) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Dérivés de triphénylalcène, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
EP0381296B1 (fr) 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Equipement pour utilisation dans le traitement de l'ostéoporose
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0260066B1 (fr) 1986-09-11 1990-05-09 National Research Development Corporation Dérivés du tamoxifène
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
DE69125394T2 (de) 1990-11-26 1997-08-21 Robert R. Omaha Nebr. Recker Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
JPH04312526A (ja) 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5180720A (en) 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
SK282166B6 (sk) 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (fr) 1993-07-22 1997-04-21 Lilly Co Eli
CZ109196A3 (en) * 1993-10-19 1996-10-16 Merck & Co Inc Combination of active compounds and a pharmaceutical preparation for treating and preventing osteoporosis
KR960705808A (ko) 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU684878B2 (en) 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
WO1995034311A1 (fr) 1994-06-13 1995-12-21 Merck & Co., Inc. Compose de piperazine provoquant la liberation de l'hormone de croissance
EP0779813A4 (fr) * 1994-09-09 1998-05-06 Procter & Gamble Phosphonates et parathormone contre l'osteoporose
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US6100301A (en) 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
JP3102896B2 (ja) 1996-05-07 2000-10-23 ファイザー インク． ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
AU3025997A (en) 1996-05-31 1998-01-05 Novo Nordisk A/S Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
HUP9904123A2 (hu) 2000-05-28
ATE405273T1 (de) 2008-09-15
CN1515254A (zh) 2004-07-28
HK1018210A1 (en) 1999-12-17
HN1996000101A (es) 1997-06-26
ZA971719B (en) 1998-08-27
PL187219B1 (pl) 2004-06-30
SI0883404T1 (sl) 2008-10-31
CZ297452B6 (cs) 2006-12-13
AP2002002661A0 (en) 2002-12-31
IS4812A (is) 1998-07-28
HUP9904123A3 (en) 2001-01-29
DZ2186A1 (fr) 2002-12-02
NO323648B1 (no) 2007-06-18
ID19886A (id) 1998-08-13
PE58998A1 (es) 1998-10-16
CA2247420A1 (fr) 1997-09-04
AP974A (en) 2001-06-12
OA10837A (en) 2001-08-13
PE20011302A1 (es) 2001-12-25
DE69637651D1 (en) 2008-10-02
GT199700009AA (es) 1999-01-23
EP1932543A3 (fr) 2012-01-04
IL154380A0 (en) 2003-09-17
UY24472A1 (es) 2000-09-29
NZ323456A (en) 2001-03-30
NO983936L (no) 1998-08-27
TR199801679T2 (xx) 2001-06-21
KR19990087337A (ko) 1999-12-27
AU1039897A (en) 1997-09-16
CO4761063A1 (es) 1999-04-27
BG102726A (en) 1999-04-30
PL328831A1 (en) 1999-02-15
AP975A (en) 2001-06-12
CA2247420C (fr) 2011-02-15
SK118398A3 (en) 2000-07-11
AP2000001962A0 (en) 2000-12-31
RU2190395C2 (ru) 2002-10-10
NO983936D0 (no) 1998-08-27
US6323232B1 (en) 2001-11-27
MA26420A1 (fr) 2004-12-20
NO20063853L (no) 1998-08-27
IL154379A0 (en) 2003-09-17
JP2002308771A (ja) 2002-10-23
EP0883404A1 (fr) 1998-12-16
EP0883404B1 (fr) 2008-08-20
CN1209064A (zh) 1999-02-24
ES2312169T3 (es) 2009-02-16
CN1242813C (zh) 2006-02-22
CL2004000119A1 (es) 2005-02-11
IL125493A0 (en) 1999-03-12
CN1515317A (zh) 2004-07-28
US20010009920A1 (en) 2001-07-26
BR9612533A (pt) 1999-07-20
BG64582B1 (bg) 2005-08-31
PT883404E (pt) 2008-11-14
JPH11504352A (ja) 1999-04-20
WO1997031640A1 (fr) 1997-09-04
AR005987A1 (es) 1999-07-21
CN1515258A (zh) 2004-07-28
DK0883404T3 (da) 2008-10-20
YU7797A (sh) 2000-10-30
US7255984B2 (en) 2007-08-14
EP1236475A3 (fr) 2003-11-05
AP1179A (en) 2003-06-30
TW464496B (en) 2001-11-21
AR060853A2 (es) 2008-07-16
EP1236475A2 (fr) 2002-09-04
EP1932543A2 (fr) 2008-06-18
UA69372C2 (en) 2004-09-15
PL187962B1 (pl) 2004-11-30
CN1515316A (zh) 2004-07-28
AP9700934A0 (en) 1997-04-30
AU703285B2 (en) 1999-03-25
HRP970118A2 (en) 1998-04-30
CZ271898A3 (cs) 1999-06-16
GT199700009A (es) 1998-07-10

Similar Documents

Publication Publication Date Title
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
TNSN99203A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
BR9911116A (pt) Processo para tratar ou reduzir o risco de adquirir uma condição selecionada dentre o grupo consistindo de aterosclerose, câncer endometrial, câncer uterino, câncer ovariano, falta de lubrificação vaginal, e perda de massa muscular, composição farmacêutica, e, kit.
TNSN99079A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
DE69514813D1 (en) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
TNSN01068A1 (fr) Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN04191A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
TNSN98104A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00230A1 (fr) Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2, 3,4-tetrahydroquinoleine
FR06C0032I1 (fr)
BE900564A (fr) Composition pharmaceutique pour le traitement d'arteriopathies peripheriques.
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
TNSN99119A1 (fr) Compositions comprenant un modulateur de recepteur d'oestrogene selectif et de l'hormone parathyroidienne, et procede pour leur preparation
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
BG103060A (bg) 19- нор- холан стероиди като неврохимични инициатори на промяната в действието на хипоталамуса причовек
IS4392A (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga